Working closely with your healthcare team to find the right medication and dose is essential
doi: 10.1016/j.cgh.2023.06.004 Summary Keywords glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 receptor, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, obesity Citation Oe Y, Omori T, Aimono E, Furukawa S, Kitakawa H, Tateno M, Sakai K and Cho KY (2025) Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide

It is not known if Semaglutide will cause thyr oid tumors or a type of thyr oid cancer called medullary thyr oid carcinoma (MTC) in people Do not use Semaglutide if you or any of your family have ever had a type of thyr oid cancer called medullary thyr oid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Do not use Semaglutide if: you or any of your family have ever had a type of thyr oid cancer called medullary thyr oid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) you have had a serious allergic reaction to semaglutide or any of the ingredients in Semaglutide Before using Semaglutide, tell your healthcare provider if you have any other medical conditions, including if you: have or have had problems with your pancreas or kidneys have type 2 diabetes and a history of diabetic retinopathy have or have had depression, suicidal thoughts, or mental health issues are pregnant or plan to become pregnant

Moreover, the use of WAC for the included medications does not reflect any rebates that might be applied for specific medical insurance companies
If you experience any side effects, consult your healthcare provider and seek medical advice.
The study tracked over 82,000 diabetes patients between 2014 and 2017